Clinical Trial Detail

NCT ID NCT04166487
Title Plasma-Adapted First-Line Pembro In NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium

Age Groups: adult senior

Additional content available in CKB BOOST